The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Rolf Kaiser
Employment or Leadership Position - Boehringer Ingelheim
Anders Mellemgaard
No relevant relationships to disclose
Jean Yves Douillard
Consultant or Advisory Role - Boehringer Ingelheim
Sergey Orlov
No relevant relationships to disclose
Maciej Jerzy Krzakowski
No relevant relationships to disclose
Joachim Von Pawel
Consultant or Advisory Role - Boehringer Ingelheim
Maya Gottfried
No relevant relationships to disclose
Igor Bondarenko
No relevant relationships to disclose
Meilin Liao
No relevant relationships to disclose
Jose Barrueco
Employment or Leadership Position - Boehringer Ingelheim
Birgit Gaschler-Markefski
Employment or Leadership Position - Boehringer Ingelheim
Silvia Novello
No relevant relationships to disclose